GP120: target for neutralizing HIV-1 antibodies
- PMID: 16551265
- DOI: 10.1146/annurev.immunol.24.021605.090557
GP120: target for neutralizing HIV-1 antibodies
Abstract
The glycoprotein (gp) 120 subunit is an important part of the envelope spikes that decorate the surface of HIV-1 and a major target for neutralizing antibodies. However, immunization with recombinant gp120 does not elicit neutralizing antibodies against multiple HIV-1 isolates (broadly neutralizing antibodies), and gp120 failed to demonstrate vaccine efficacy in recent clinical trials. Ongoing crystallographic studies of gp120 molecules from HIV-1 and SIV increasingly reveal how conserved regions, which are the targets of broadly neutralizing antibodies, are concealed from immune recognition. Based on this structural insight and that from studies of antibody structures, a number of strategies are being pursued to design immunogens that can elicit broadly neutralizing antibodies to gp120. These include (a) the construction of mimics of the viral envelope spike and (b) the design of antigens specifically tailored to induce broadly neutralizing antibodies.
Similar articles
-
Importance of conformation on the neutralizing antibody response to HIV-1 gp120.Biotechnol Ther. 1991;2(1-2):63-89. Biotechnol Ther. 1991. PMID: 1726963
-
The antigenic structure of the HIV gp120 envelope glycoprotein.Nature. 1998 Jun 18;393(6686):705-11. doi: 10.1038/31514. Nature. 1998. PMID: 9641684
-
Rationally Designed Vaccines Targeting the V2 Region of HIV-1 gp120 Induce a Focused, Cross-Clade-Reactive, Biologically Functional Antibody Response.J Virol. 2016 Nov 28;90(24):10993-11006. doi: 10.1128/JVI.01403-16. Print 2016 Dec 15. J Virol. 2016. PMID: 27630234 Free PMC article.
-
Challenges for structure-based HIV vaccine design.Curr Opin HIV AIDS. 2009 Sep;4(5):431-40. doi: 10.1097/COH.0b013e32832e6184. Curr Opin HIV AIDS. 2009. PMID: 20048708 Review.
-
Broadly neutralizing antibodies against HIV-1: templates for a vaccine.Virology. 2013 Jan 5;435(1):46-56. doi: 10.1016/j.virol.2012.10.004. Virology. 2013. PMID: 23217615 Review.
Cited by
-
Designing a soluble near full-length HIV-1 gp41 trimer.J Biol Chem. 2013 Jan 4;288(1):234-46. doi: 10.1074/jbc.M112.424432. Epub 2012 Nov 26. J Biol Chem. 2013. PMID: 23184960 Free PMC article.
-
Rational design of vaccines to elicit broadly neutralizing antibodies to HIV-1.Cold Spring Harb Perspect Med. 2011 Sep;1(1):a007278. doi: 10.1101/cshperspect.a007278. Cold Spring Harb Perspect Med. 2011. PMID: 22229123 Free PMC article. Review.
-
Single-Chain Soluble BG505.SOSIP gp140 Trimers as Structural and Antigenic Mimics of Mature Closed HIV-1 Env.J Virol. 2015 May;89(10):5318-29. doi: 10.1128/JVI.03451-14. Epub 2015 Mar 4. J Virol. 2015. PMID: 25740988 Free PMC article.
-
A Chimeric HIV-1 gp120 Fused with Vaccinia Virus 14K (A27) Protein as an HIV Immunogen.PLoS One. 2015 Jul 24;10(7):e0133595. doi: 10.1371/journal.pone.0133595. eCollection 2015. PLoS One. 2015. PMID: 26208356 Free PMC article.
-
Production and characterization of human anti-V3 monoclonal antibodies from the cells of HIV-1 infected Indian donors.Virol J. 2012 Sep 12;9:196. doi: 10.1186/1743-422X-9-196. Virol J. 2012. PMID: 22971578 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
